Navigation Links
World's first delivery of intra-arterial Avastin directly into brain tumor
Date:11/17/2009

NEW YORK (Nov. 17, 2009) -- Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. This novel intra-arterial (IA) technique may expose the cancer to higher doses of the drug therapy, while possibly sparing the patient common side effects of receiving the drug intravenously (IV) or throughout their body.

The investigative procedure -- called super selective intra-arterial cerebral infusion of Avastin -- has been successfully performed on five patients with promising results. Details of the first case are scheduled for publication in the next issue of Journal of Experimental Therapeutics and Oncology.

The researchers are currently enrolling patients for the Phase I study, which will test the safety and tolerability of this new method of drug delivery. If proven successful, NewYork-Presbyterian/Weill Cornell physician-scientists believe that this promising method may one day offer patients a new and better therapy for glioblastoma multiforme (GBM), a common type of brain cancer that has not responded well to currently available therapies. In addition, the authors believe that this technique may herald the birth of a new field of "interventional neuro-oncology."

"We believe that infusing Avastin directly via the cerebral arteries deep into the site of the brain tumor may help to kill off the cancer cells hiding within the tumor and adjacent brain tissue," explains co-author and study co-principal investigator (PI) Dr. John A. Boockvar, associate professor of neurological surgery at Weill Cornell Medical College and director of the brain tumor research laboratory at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

"We are combining the latest in drug treatment with a revolutionary delivery technique, which could potentially be more effective than currently available treatments," says co-author and co-PI, Dr. Howard Riina, co-director of interventional neuroradiology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center and associate professor of neurological surgery, neurology and radiology at Weill Cornell Medical College.

Because of the blood-brain barrier (BBB), which prevents many IV-administered drugs from penetrating the blood vessel walls sufficiently in order to get into the brain, no one knows for sure if current drugs actually get into the brain after IV infusion.

"This new technique may be a way to get through that barrier and deliver higher doses of drug to the tumor with less toxicity to the patient," says Dr. Boockvar.

To deliver the drug, neurosurgeons direct a hair-thin microcatheter through blood vessels in the body, via the carotid artery running up the neck, and then into the smaller arteries deep in the brain. Upon arriving at the tumor site, a drug to open the blood-brain barrier is injected. After the BBB is temporarily opened -- a window of time lasting approximately five minutes -- the chemotherapeutic agent Avastin is injected directly into the malignant tumor.

Participants in the trial will be given varying doses of the drug in order to test which dose is best tolerated. Following this Phase I trial, the researchers plan to immediately begin a Phase II trial to test the technique's efficacy.

"This potential new drug delivery system demonstrates translational research from the Brain and Spine Center of NewYork-Presbyterian Hospital/Weill Cornell Medical Center at its best," says Dr. Philip E. Stieg, chairman of neurological surgery at Weill Cornell Medical College and neurosurgeon-in-chief at NewYork-Presbyterian/Weill Cornell. "If proven successful, it is a promising move forward for patients dealing with resistant brain tumors."

The current standard of care is to give patients with GBM the drug bevacizumab (Avastin) intravenously (IV) -- delivering the drug directly into a vein. The drug works by slowing the growth of new blood vessels within tumors, cutting off the life-giving blood and then causing the cancer cells to die. In May 2009, the FDA approved Avastin for the treatment of GBM.


'/>"/>

Contact: John Rodgers
jdr2001@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Related medicine news :

1. Paging All Science and Medical Mavens: Get To Philadelphia Stat for Body Worlds and Beyond
2. BODY WORLDS Anatomical Exhibitions of Donor Bodies Receives 28 Millionth Visitor.
3. Variants of umami taste receptor contribute to our individualized flavor worlds
4. Scienceroll.com on the Medical Implications of Virtual Worlds
5. Gunther Von Hagens BODY WORLDS and KORPERWELTEN - Not Affiliated With Paris Copycat Display
6. BODY WORLDS Exhibition Uses Lung Specimens to Launch Anti-Smoking Campaign at the San Diego Natural History Museum
7. HHS AIDS.gov to Use Blogs, Virtual Worlds, and Social Networks to Deliver HIV Information for World AIDS Day 2008
8. Gunther von Hagens BODY WORLDS Exhibitions Welcome Specimens From Worlds First Living Body Donor for Plastination
9. Gunther Von Hagens BODY WORLDS Exhibitions Mark 25th Million Visitor Milestone
10. California Science Center Welcomes 1-Millionth BODY WORLDS Visitor
11. Specimens in BODY WORLDS Exhibitions Stem Primarily from German Body Donation Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... and LONDON, UK (PRWEB) , ... May 06, 2016 , ... ... for his success in changing the way the pharmaceutical industry conducts clinical trials. This ... the world’s most influential people in pharma, and he was honored as a Tech ...
(Date:5/6/2016)... ... ... US Sports Camps has collaborated with State Rugby Organization (SRO), Rugby Oregon, ... Employing world-class rugby figures, including former Team USA players and college coaches, this program ... match play, fitness and more. , “US Sports Camps is honored to be working ...
(Date:5/6/2016)... ... 2016 , ... Innovations with Ed Begley Jr. announced today ... via Discovery Channel. Dates and show times TBA. , AsedaSciences® was established in ... innovative cellular analysis. In this segment, viewers will learn how AsedaSciences utilizes flow ...
(Date:5/6/2016)... ... ... Online HR/benefits platforms offer a range of benefits functions to employers of ... plans. “ The Rapid Emergence of Online Benefits Firms: Strategies for Health Plans and ... offer an accurate picture of online benefits today, and the possible risks and rewards. ...
(Date:5/6/2016)... ... , ... Canadian author Mark Black is a speaker, author, and life strategy coach ... world … with the help of his publisher Strategic Book Group and its subsidiary ... hospital bed waiting for a miracle: He needed a heart and double-lung transplant. From this ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... CITY, Mo. , May 3, 2016 /PRNewswire/ ... Kansas Medical Center,s Institute for Advancing Medical Innovation ... and commercialize new drugs, diagnostics and medical devices. ... provides BioNovus Innovations with rights to license, develop ... "This partnership represents ...
(Date:5/3/2016)... Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities and increase market presence. ... ... ... ... Sino-German High-Tech Fund ...
(Date:5/3/2016)... 3, 2016 ACME Markets, ... and Delaware County Councilman Dave White ... in all ACME pharmacies across ... Control and Prevention (CDC), naloxone has saved 26,463 lives nationwide over ... Delaware County were authorized to administer naloxone ...
Breaking Medicine Technology: